Trial
NCT03485729
ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
Jazz Pharmaceuticals
Collaborators
Oncoceutics, Inc.
Condition
Endometrial Cancer Recurrent
Intervention
Dordaviprone (ONC201)
Why stopped
This study was terminated due to a change in the Sponsor's corporate priorities. The decision to terminate the study was not based on any safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-12-24